Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry

[1]  Zhang Jun,et al.  Interpretation of NCCN Clinical Practice Guidelines in Oncology:Cervical Cancer (Version 1.2016) , 2016 .

[2]  A. Horwich,et al.  Guidelines on Testicular Cancer: 2015 Update. , 2015, European urology.

[3]  Derick R. Peterson,et al.  Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  L. Habel,et al.  Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. , 2015, American journal of public health.

[5]  S. Fosså,et al.  Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study. , 2015, Anticancer research.

[6]  S. Altekruse,et al.  Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) Registries. , 2014, Journal of the National Cancer Institute. Monographs.

[7]  O. Ståhl,et al.  One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  R. Wilder,et al.  Outcomes and treatment patterns as a function of time in stage IS testicular seminoma: a population-based analysis. , 2014, Cancer epidemiology.

[9]  T. Powles,et al.  Active surveillance is the preferred approach to clinical stage I testicular cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  A. Horwich,et al.  EAU guidelines on testicular cancer: 2011 update. , 2011, European urology.

[11]  F. Montorsi,et al.  Trends of Retroperitoneal Lymphadenectomy Use in Patients with Nonseminomatous Germ Cell Tumor of the Testis: A Population-Based Study , 2011, Annals of Surgical Oncology.

[12]  G. Pond,et al.  Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. , 2011, European urology.

[13]  M. Gleave,et al.  Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  M. Jewett,et al.  Surveillance in stage I nonseminomatous germ cell tumours of the testis , 2009, BJU international.

[15]  M. Moore,et al.  Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. , 2005, The Canadian journal of urology.

[16]  J. Bachaud,et al.  Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion. , 2004, European urology.

[17]  M. Williams,et al.  Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. , 2004, Urology.

[18]  J. Baniel,et al.  Complications of primary retroperitoneal lymph-node dissection for low-stage testicular cancer , 2004, World Journal of Urology.

[19]  P. Albers,et al.  Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group. , 2003, The Journal of urology.

[20]  F. Burkhard,et al.  Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. , 2001, The Journal of urology.

[21]  G. Rustin,et al.  Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. , 2000, European journal of cancer.

[22]  M. Williams,et al.  Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  H. D. de Bruijn,et al.  Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Swanson Da.  The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors. , 1993 .

[25]  D. Swanson.  The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors. , 1993, Seminars in urology.

[26]  L. Mazzucchelli,et al.  Adjuvant chemotherapy after orchiectomy in high-risk patients with clinical stage I non-seminomatous testicular cancer. , 1993, European urology.

[27]  V. Harvey,et al.  Results of the surveillance policy of stage I non-seminomatous germ cell testicular tumours. , 1992, British journal of urology.